- Home
- NRIM vs SRDX Comparison
NRIM vs SRDX Comparison
Compare NRIM & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- SRDX
- Stock Information
- Founded
- NRIM 1990
- SRDX 1979
- Country
- NRIM United States
- SRDX United States
- Employees
- NRIM N/A
- SRDX N/A
- Industry
- NRIM Savings Institutions
- SRDX Medical/Dental Instruments
- Sector
- NRIM Finance
- SRDX Health Care
- Exchange
- NRIM Nasdaq
- SRDX Nasdaq
- Market Cap
- NRIM 514.9M
- SRDX 415.4M
- IPO Year
- NRIM N/A
- SRDX 1998
- Fundamental
- Price
- NRIM $96.27
- SRDX $30.57
- Analyst Decision
- NRIM
- SRDX Buy
- Analyst Count
- NRIM 0
- SRDX 2
- Target Price
- NRIM N/A
- SRDX $43.00
- AVG Volume (30 Days)
- NRIM 69.1K
- SRDX 88.8K
- Earning Date
- NRIM 07-23-2025
- SRDX 07-30-2025
- Dividend Yield
- NRIM 2.63%
- SRDX N/A
- EPS Growth
- NRIM 46.48
- SRDX N/A
- EPS
- NRIM 7.52
- SRDX N/A
- Revenue
- NRIM $164,695,000.00
- SRDX $121,575,000.00
- Revenue This Year
- NRIM N/A
- SRDX N/A
- Revenue Next Year
- NRIM $7.05
- SRDX $3.70
- P/E Ratio
- NRIM $12.95
- SRDX N/A
- Revenue Growth
- NRIM 26.35
- SRDX N/A
- 52 Week Low
- NRIM $55.58
- SRDX $26.00
- 52 Week High
- NRIM $100.21
- SRDX $42.44
- Technical
- Relative Strength Index (RSI)
- NRIM 66.91
- SRDX 57.70
- Support Level
- NRIM $97.35
- SRDX $28.90
- Resistance Level
- NRIM $100.21
- SRDX $31.06
- Average True Range (ATR)
- NRIM 2.20
- SRDX 0.85
- MACD
- NRIM 0.53
- SRDX 0.08
- Stochastic Oscillator
- NRIM 81.39
- SRDX 64.07
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.